- Home
- AMRN vs KYTX Comparison
AMRN vs KYTX Comparison
Compare AMRN & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- KYTX
- Stock Information
- Founded
- AMRN 1989
- KYTX 2018
- Country
- AMRN Ireland
- KYTX United States
- Employees
- AMRN N/A
- KYTX N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- KYTX
- Sector
- AMRN Health Care
- KYTX
- Exchange
- AMRN Nasdaq
- KYTX NYSE
- Market Cap
- AMRN 236.4M
- KYTX 242.1M
- IPO Year
- AMRN 1993
- KYTX 2024
- Fundamental
- Price
- AMRN $0.50
- KYTX $4.35
- Analyst Decision
- AMRN Hold
- KYTX Buy
- Analyst Count
- AMRN 2
- KYTX 5
- Target Price
- AMRN N/A
- KYTX $23.40
- AVG Volume (30 Days)
- AMRN 1.2M
- KYTX 237.0K
- Earning Date
- AMRN 10-30-2024
- KYTX 11-13-2024
- Dividend Yield
- AMRN N/A
- KYTX N/A
- EPS Growth
- AMRN N/A
- KYTX N/A
- EPS
- AMRN N/A
- KYTX N/A
- Revenue
- AMRN $241,021,000.00
- KYTX N/A
- Revenue This Year
- AMRN N/A
- KYTX N/A
- Revenue Next Year
- AMRN N/A
- KYTX N/A
- P/E Ratio
- AMRN N/A
- KYTX N/A
- Revenue Growth
- AMRN N/A
- KYTX N/A
- 52 Week Low
- AMRN $0.50
- KYTX $4.32
- 52 Week High
- AMRN $1.37
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- AMRN 32.91
- KYTX 33.83
- Support Level
- AMRN $0.54
- KYTX $5.01
- Resistance Level
- AMRN $0.58
- KYTX $5.62
- Average True Range (ATR)
- AMRN 0.04
- KYTX 0.39
- MACD
- AMRN -0.01
- KYTX -0.03
- Stochastic Oscillator
- AMRN 2.97
- KYTX 2.19
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.